Moneycontrol PRO
HomeNewsOpinionCOVID-19 | What the positive case-to-test ratio tells us about the pandemic

COVID-19 | What the positive case-to-test ratio tells us about the pandemic

Analysis of positive cases-to-test ratio show that to beat the virus we need to focus on decentralised policy making

April 29, 2020 / 11:49 IST
Reuters

Aakanksha Arora, Mahima and Aasheerwad Dwivedi

 The COVID-19 outbreak has reached every continent on Earth, except Antarctica. The disease has upended life across the globe, shutting down entire countries within months. One specific statistic i.e. proportion of people tested positive out of total tests performed lies at the heart of understanding the spread of the pandemic. This number not only tells us about the prevalence of the infection, but also about who are actually being tested.

An insightful way to analyse this number is to interpret it in terms of sensitivity and specificity of the testing criteria and prevalence of the virus. At any point of time, who will be tested and who will not, is dependent on specificity of testing criteria. During the early stages of any outbreak the testing criteria usually has high specificity, i.e. only people with very specific conditions are eligible for testing. In the case of COVID-19, these conditions include international travel history, high fever, dry cough, etc. Due to high specificity, fewer people get tested.

On the other hand, high sensitivity in testing criteria attempts to capture the majority of the population which helps in containment interventions. To get a deeper insight, we use Bayes’ theorem to formulate ‘Proportion of tests positive’ in terms of sensitivity, specificity and prevalence.

test postive 28042020

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

All the efforts related to controlling the pandemic can be seen as an attempt to drive this ratio down. There are only two ways of doing so — lowering the prevalence of the infection and/or by reducing the specificity of testing criteria i.e. testing more and more population.

Most countries, including India, started with ‘highly specific’ testing criteria and broadened it gradually. The ‘Proportion of tests positive’ would be higher in a ‘highly specific’ testing criteria as only the people who possess specific pre-requisites would be tested. As we start testing more population including asymptomatic people, this ratio reduces.

In India, the percentage of positive cases to total tests done was around 1-2 initially. It started increasing over time as testing criteria was limited to high risk group. It is a generally noted international trend as well that this ratio increases before it falls or flattens. The testing criterion was gradually broadened, and a massive increase in testing was also brought about, after which the positive test percentage has flattened. However, it has not yet reduced. One possible explanation of this could be that the prevalence of infection has not declined that sharply, counter-balancing the wide expansion in testing (reducing specificity). In the last three weeks, the number of tests in India rose from 100,000 to over 600,000.

flattening of positive case 28042020

However, the picture varies widely across states. While the positive cases to test ratio is decreasing sharply for Tamil Nadu, Kerala, Odisha and Karnataka, it is still increasing in Maharashtra and Gujarat. The ratio, although high, is falling slowly in Delhi and Madhya Pradesh.

major states 28042020

On the basis of the Bayesian framework, it seems that the prevalence of infection has decreased in Kerala, Karnataka, Odisha and Tamil Nadu — whereas in Maharashtra, Gujarat, Madhya Pradesh and Delhi the prevalence seems to have still not declined, which is counterbalancing the decreased specificity of the tests being conducted.

We must also note that states are testing at different rates, with Delhi conducting more tests per million in comparison to other states. Of course, for an accurate statistical analysis, many other factors, such as demography, mobility, health infrastructure and many unknowns need to be accounted for.

We have been able to prevent the virus spread to grow exponentially in India. However, states are at different stages in terms of reduction in the prevalence. In this light, rather than ‘one size fit all’ policy, decision needs to be taken at regional levels. The government’s decision to identify hotspot districts and containment zones, and take decisions accordingly is a step in right direction.

Aakanksha Arora is Deputy Director in Ministry of Finance, Mahima is Consultant in Ministry of Finance, and Aasheerwad Dwivedi is Assistant Professor, Shri Ram College of Commerce, New Delhi. Views are personal.

Moneycontrol Contributor
Moneycontrol Contributor
first published: Apr 29, 2020 10:00 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347